ArticleFrontiers in immunology2024

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.

Brandon Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.